Lupo S, Santarelli MT, Kneitschel R, Bortolozzi R, Navarret N, Taborda M; International Conference on AIDS.

Int Conf AIDS. 1994 Aug 7-12; 10: 147 (abstract no. PB0013).

Hospital Centenario, University of Rosario, Argentina.

OBJECTIVE: to describe the epidemiology, clinical aspects and antiretroviral therapy in a group of HIV (+) in Rosario City, Argentina. MATERIAL: since 1988 until 9/93 a total of 87 HIV (+) women were followed in our institution. Median age was 26 range (15-55); 16% initial stage 4 (WHO Staging System); heterosexual transmission 67%, IVDU 31%, blood transfusion 2%; married 43%, single 44%, 59% had children, 3% pregnant women; 60% male sexual partners with positive serology; median baseline CD4 count 605 range (69-1192) and baseline lymphocytes count 1848 range (456-3350). Median event times were estimated from Kaplan-Meier curves. RESULTS: heterosexual transmission 58/87 (67%) was the dominant route in our population. Nine (10%) of children had positive serology for HIV, one of them is dead. More frequent opportunistic infections more frequent were: PCP 17 (19%), Tuberculosis 8 (9%) and Cryptococcal meningitis 5 (6%). Forty-one pts received antiretroviral therapy: AZT (46%), DDI (3%) and AZT+DDC (11%), median time to treatment was 25 months (mo); estimated SV at 60 mo was: 85% and 71% (p = 0.6789) for pts with or without therapy respectively. Twenty-nine (33%) pts progressed to stage 4 with a median time to progression of 42 mo and 10 pts died; estimated probability of survival was 74% at 60 mo. CONCLUSION: 47% of patients started antiretroviral therapy due to progression of HIV infection. Heterosexual transmission was the predominant way in this population. PCP was the most frequent complication and Tuberculosis (pulmonary 3, extrapulmonary 5) was the second opportunistic infection. There was no neoplastic complications.

Publication Types:

• Meeting Abstracts

Keywords:

• AIDS Vaccines
• Acquired Immunodeficiency Syndrome
• Antiretroviral Therapy, Highly Active
• Argentina
• CD4 Lymphocyte Count
• Child
• Didanosine
• Disease Progression
• Drug Therapy, Combination
• Female
• HIV Infections
• HIV Seropositivity
• Humans
• Male
• Pregnancy
• Tuberculosis
• Zalcitabine
• Zidovudine
• drug therapy
• therapy
• transmission

Other ID:

• 94369445

UI: 102208271

From Meeting Abstracts